These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24871638)

  • 21. Direct oral anticoagulants in the treatment of pulmonary embolism.
    Eldredge JB; Spyropoulos AC
    Curr Med Res Opin; 2018 Jan; 34(1):131-140. PubMed ID: 28771049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Kearon C; Akl EA; Comerota AJ; Prandoni P; Bounameaux H; Goldhaber SZ; Nelson ME; Wells PS; Gould MK; Dentali F; Crowther M; Kahn SR
    Chest; 2012 Feb; 141(2 Suppl):e419S-e496S. PubMed ID: 22315268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
    Turpie AGG; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Ageno W
    Thromb Res; 2017 Jul; 155():23-27. PubMed ID: 28477534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Old versus new anticoagulants: focus on pharmacology.
    Benmira S; Banda ZK; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):120-37. PubMed ID: 20337579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
    Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.
    Kubitza D; Haas S
    Expert Opin Investig Drugs; 2006 Aug; 15(8):843-55. PubMed ID: 16859389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
    Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
    Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ
    Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.
    Fermann GJ; Erkens PM; Prins MH; Wells PS; Pap ÁF; Lensing AW
    Acad Emerg Med; 2015 Mar; 22(3):299-307. PubMed ID: 25716463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
    Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
    Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
    Barco S; Lankeit M; Binder H; Schellong S; Christ M; Beyer-Westendorf J; Duerschmied D; Bauersachs R; Empen K; Held M; Schwaiblmair M; Fonseca C; Jiménez D; Becattini C; Quitzau K; Konstantinides S
    Thromb Haemost; 2016 Jul; 116(1):191-7. PubMed ID: 27010343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [From heparin to apixaban: anticoagulants cut both ways?].
    Hartung K; Meyer F; Bock F; Isermann B
    Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological management of pulmonary embolism.
    Gouin B; Robert-Ebadi H; Righini M; Blondon M
    Expert Opin Pharmacother; 2017 Jan; 18(1):79-93. PubMed ID: 27917690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].
    Bátorová A
    Vnitr Lek; 2009 Mar; 55(3):295-301. PubMed ID: 19378862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.